Probucol, an antioxidant, is proposed as a potential agent to prevent adriamycin cardiomyopathy by reducing oxidative stress, warranting future clinical trials.
Does probucol prevent adriamycin cardiomyopathy?
This review proposes that probucol, an antioxidant effective in both lipid and water phases, should be evaluated in clinical trials to prevent adriamycin-induced cardiomyopathy.
Current knowledge about adriamycin cardiomyopathy indicates that the major cause of this condition is increased oxidative stress although the drug's antitumor action in patients may involve other mechanisms. Controversies about the different antioxidants in preventing cardiomyopathy likely stem from the fact that antioxidants must be effective in both the lipid and water phases, and the dose must be optimal, in order to be protective. Probucol, an antioxidant and promoter of endogenous antioxidants, is one such agent. Conducting clinical trials with an optimal dose of probucol is the next step and should make this great anticancer drug safer and more efficient in the fight against the cancer.
Singal et al. (1997) conducted a review in Adriamycin cardiomyopathy. Probucol was evaluated. Probucol, an antioxidant, is proposed as a potential agent to prevent adriamycin cardiomyopathy by reducing oxidative stress, warranting future clinical trials.